Is vitamin C supplementation safe in adults, particularly those with chronic kidney disease, on dialysis, or with a history of calcium‑oxalate kidney stones, and what dosage is recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vitamin C and Kidney Safety

Vitamin C supplementation should be strictly limited to 100 mg/day in adults with chronic kidney disease or on dialysis to prevent dangerous oxalate accumulation and kidney damage, while those with a history of calcium-oxalate kidney stones should avoid supplementation above this threshold due to increased crystallization risk. 1

Dosing Recommendations by Clinical Scenario

Chronic Kidney Disease (Not on Dialysis)

  • Limit total vitamin C intake to 100 mg/day from all sources (diet plus supplements) for CKD Stage 1-4 patients to prevent oxalate accumulation in plasma and soft tissues 1
  • This conservative limit is necessary because impaired kidney function cannot adequately clear oxalate, the metabolic end-product of vitamin C 1

Hemodialysis Patients

  • The safe upper limit is 100 mg/day for routine supplementation in chronic hemodialysis patients 1
  • Hemodialysis patients lose approximately 68 mg of vitamin C daily in dialysate effluent, creating a deficiency risk that must be balanced against toxicity 1
  • Water-soluble vitamin monitoring and replacement is essential due to dialysis losses and restricted fruit intake 1, 2
  • Never exceed 100 mg/day in chronic hemodialysis to prevent oxalate accumulation 1

Continuous Renal Replacement Therapy (CRRT)

  • During critical illness requiring CRRT, higher doses of 2-3 g/day IV may be necessary in the acute phase due to increased utilization and effluent losses 1
  • This exception applies only during acute critical illness, not chronic management 1

Calcium-Oxalate Stone Formers

  • Restrict vitamin C intake to approximately 100 mg/day in patients with recurrent calcium oxalate stones 3
  • Supplementation with 1-2 g/day significantly increases urinary oxalate excretion (from 31-34 mg/24h to 48-50 mg/24h) and calcium oxalate crystallization risk (Tiselius index increases from 0.92-0.99 to 1.43-1.61) 4
  • Even in healthy subjects, high-dose vitamin C increases oxalate excretion and crystallization risk 4

Critical Safety Considerations

Oxalate Toxicity Risk

  • Excessive vitamin C intake results in increased oxalate concentrations in plasma and soft tissues, particularly dangerous in renal impairment 1
  • A recent case report documented renal oxalosis and progressive kidney disease in a patient consuming 3 g daily of vitamin C during COVID-19, demonstrating that high doses can cause irreversible kidney damage even in previously stable CKD patients 5
  • The risk is real and clinically significant—prompt recognition and cessation is critical to prevent permanent damage 5

Monitoring Requirements

  • Monitor serum vitamin C levels and adjust supplementation based on individual dialysis losses and clinical status 1
  • Closely monitor patients on prolonged renal replacement therapy for signs of oxalate accumulation 1
  • Electrolyte abnormalities must be monitored in patients with AKI or CKD receiving kidney replacement therapy 1

Common Pitfalls to Avoid

  • Do not rely on older studies suggesting safety of high-dose vitamin C—older assays favored in vitro conversion of ascorbic acid to oxalate during sample processing, artificially inflating oxalate measurements 3
  • Do not assume that because vitamin C is water-soluble it is automatically safe in kidney disease—the metabolic conversion to oxalate creates a lipid-soluble toxic metabolite that accumulates 1
  • Do not extrapolate general population recommendations to CKD patients—the 90 mg/day recommendation for healthy men and 75 mg/day for women does not apply to those with impaired renal function 2
  • Beware of over-the-counter supplements marketed for immune support—patients often dramatically increase intake during illness (as seen during COVID-19 pandemic) without understanding kidney risks 5

Special Population Considerations

Pediatric Dialysis Patients

  • Lower supplemental doses are required—infants on automated peritoneal dialysis receiving 140% of RDA from diet need only 15 mg/day supplement to reach 180% of RDA 1

Malnourished Dialysis Patients with Wounds

  • Test for vitamin C deficiency and supplement appropriately with 100 mg/day if deficient 1
  • The 100 mg/day limit still applies even in wound healing scenarios 1

References

Guideline

Vitamin C Dosing in Renal Impairment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Nutritional Management for CKD-5 Hemodialysis Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

No contribution of ascorbic acid to renal calcium oxalate stones.

Annals of nutrition & metabolism, 1997

Related Questions

What is the appropriate daily vitamin C (ascorbic acid) supplement dose for a generally healthy adult without contraindications (e.g., renal disease, calcium oxalate nephrolithiasis, or iron overload), including recommendations for men, women, pregnant or lactating women, and smokers, while staying below the tolerable upper intake level?
Does oral vitamin C alkalinize urine?
What oral vitamin C dose is recommended for a generally healthy adult without renal disease, kidney stones, or glucose‑6‑phosphate dehydrogenase deficiency?
Is there a correlation between excessive ascorbic acid (Vitamin C) intake and the formation of nephrolithiasis (kidney stones)?
Does vitamin C require renal dosing in patients with impaired renal function?
Which oral antibiotics are appropriate for step‑down therapy after intravenous piperacillin‑tazobactam in a clinically stable patient?
In a patient with type 2 diabetes and impaired renal function (eGFR ≥60, 45‑59, or <45 mL/min/1.73 m²), how should evogliptin and linagliptin be dosed and which agent is preferred for safety and efficacy?
What is the recommended management of supraspinatus calcific tendinitis?
What are the typical clinical manifestations of Crohn disease in women?
In a patient with type 2 diabetes mellitus who has renal impairment, is elderly, or has cardiovascular risk, should linagliptin be preferred over evogliptin as the second‑line oral therapy?
What are the clinical indications for adding insulin therapy in a patient with type 2 diabetes, including severe hyperglycemia (fasting or random glucose ≥300 mg/dL with classic symptoms or ketosis/diabetic ketoacidosis), HbA1c ≥10 % (or ≥9 % with symptomatic hyperglycemia), failure of dual or triple oral therapy or glucagon‑like peptide‑1 (GLP‑1) receptor agonist/sodium‑glucose co‑transporter‑2 (SGLT‑2) inhibitor regimen after ≥3 months, pregnancy or planning pregnancy, contraindications or intolerance to oral agents such as estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m², acute illness or peri‑operative periods, and persistent glucotoxicity (>250 mg/dL)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.